[Targeted therapies, prognostic and predictive factors in endocrine oncology].

Abstract : A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.
Type de document :
Article dans une revue
Annales d'Endocrinologie, Elsevier Masson, 2013, 74 Suppl 1, pp.S13-22. 〈10.1016/S0003-4266(13)70017-9〉
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00931413
Contributeur : Marc Lombes <>
Soumis le : vendredi 16 mai 2014 - 17:09:52
Dernière modification le : jeudi 30 novembre 2017 - 01:17:50
Document(s) archivé(s) le : samedi 8 avril 2017 - 15:54:09

Fichiers

Hescot_Must_Ultimate_Jul_16.pd...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Ségolène Hescot, Eric Baudin, Françoise Borson-Chazot, Marc Lombes. [Targeted therapies, prognostic and predictive factors in endocrine oncology].. Annales d'Endocrinologie, Elsevier Masson, 2013, 74 Suppl 1, pp.S13-22. 〈10.1016/S0003-4266(13)70017-9〉. 〈inserm-00931413〉

Partager

Métriques

Consultations de la notice

806

Téléchargements de fichiers

762